ArticleTherapeutic advances in medical oncology2023
Author response to 'Comment on "Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab
Robert Hettle et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.